Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
Lexicon Pharmaceuticals (Nasdaq: LXRX) will announce its third quarter 2022 financial results on November 9, 2022, after market close. A conference call will follow at 5:00 p.m. ET to discuss results and provide business updates. Interested parties can access the call at the provided dial-in numbers and listen to a replay for 14 days. Lexicon focuses on pioneering innovative medicines through its Genome5000™ program, targeting significant therapeutic proteins across various diseases, with ongoing development in heart failure, diabetes, and more.
- Lexicon has advanced one medicine to market and continues to develop promising candidates.
- Ongoing clinical and preclinical development in several key therapeutic areas.
- Risks associated with meeting capital requirements and regulatory approvals.
- Potential delays in clinical development timelines for drug candidates.
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update.
Dial-in Information
Dial-in Number: (888) 886-7786
Conference ID: 70766912
Replay Information
Dial-in Number: (877) 674-6060
Playback Passcode: 766912 #
The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Inquiries:
Mike Kelly
Lexicon Pharmaceuticals, Inc.
mkelly@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals release its third quarter 2022 financial results?
What time is the Lexicon Pharmaceuticals conference call?
What is Lexicon Pharmaceuticals' stock symbol?
Where can I access the replay of Lexicon Pharmaceuticals' conference call?
What are Lexicon Pharmaceuticals' main therapeutic focuses?
